Top Market Players in Global AI in Breast Imaging Market
Introduction
AI in breast imaging refers to the application of artificial intelligence (AI) technologies, particularly machine learning and deep learning algorithms, in the field of medical imaging for breast-related conditions. Breast imaging plays a crucial role in the early detection, diagnosis, and monitoring of breast cancer and other breast-related diseases. AI has been integrated into various aspects of breast imaging to enhance the accuracy, efficiency, and effectiveness of these processes.
Market Analysis
The artificial intelligence in breast imaging in terms of revenue was worth US$ 491.4 Million in 2022 and is expected to reach US$ 2,389.5 Million in 2029, growing at a CAGR of 25.5% from 2021 to 2029.
Artificial intelligence (AI) has emerged as a powerful and influential tool across various domains, including breast imaging. By harnessing machine learning and deep learning techniques, AI has transformed four essential aspects of breast imaging: screening and detection, diagnosis, disease monitoring, and data management. Breast cancer, one of the most prevalent cancers affecting women worldwide, poses complex challenges in medical decision-making. In 2020 alone, there were 2.3 million new cases of breast cancer and 685,000 related deaths globally, with approximately 3.8 million women having a history of breast cancer in the United States as of 2022, encompassing both current and past patients.
Market Players in Global AI in Breast Imaging Market
Philips is a pioneering company with a remarkable history spanning over 130 years, founded in 1891 by Frederik Philips and his son, Gerard, in Eindhoven, the Netherlands. Its visionary approach led to the development of cost-effective, reliable electric incandescent light bulbs, which laid the foundation for the company's journey towards groundbreaking innovations that have consistently improved people's lives. Over the years, Philips has continued to evolve and adapt to the changing social and economic landscape. In the 1900s, it became the largest private employer in the Netherlands, demonstrating its commitment to social responsibility by investing in housing, healthcare, and sports for its employees. Embracing a human-centered design philosophy called 'Design for Life' in the 1990s, the company focused on creating products that were easier to use and provided enhanced user experiences, especially in the healthcare sector.
Today, Philips remains dedicated to its purpose of improving people's health and well-being through meaningful innovation. The company's diverse portfolio of health technology solutions supports value-based care across the entire health continuum. Notably, the Philips AI Breast feature is a testament to their dedication to advancing healthcare technology. This innovative feature enables visual mapping of screened breast anatomy, ensuring full coverage during the acquisition phase, with images stored for post-examination review. The ability to bookmark key images for quick review, auto-annotate images, and retrieve quick orthogonal views enhances workflow and documentation, showcasing Philips' commitment to improving patient care.
Siemens Healthcare GmbH was established in 1847 and has its headquarters in Erlangen, Germany. Siemens Healthcare GmbH is a key player in the Breast Imaging Market for Artificial Intelligence (AI). Siemens Healthcare, with a strong focus on innovation and the most modern equipment, has used AI to transform breast imaging and overcome the issues associated with early detection and accurate diagnosis of breast cancer. Siemens Healthcare's breast imaging systems have considerably enhanced the efficiency and accuracy of diagnostic operations by utilizing AI algorithms and machine learning approaches. With the use of AI, the company's imaging systems can now analyze mammograms and other breast imaging data with amazing precision, assisting radiologists in identifying tiny anomalies that may suggest probable cancers.
Furthermore, Siemens Healthcare's dedication to R&D is demonstrated by its engagement with renowned medical institutes and active participation in clinical studies. By constantly improving and updating its AI algorithms, the firm ensures that its breast imaging products remain in the most current state of medical technology, providing accurate and prompt diagnoses that can ultimately save lives. Siemens Healthcare's AI-driven breast imaging technology has improved diagnostic accuracy while also streamlining workflow operations, resulting in shorter wait times for patients and increased operational efficiency for healthcare institutions. This simplified strategy allows healthcare providers to handle a higher volume of cases, which improves patient outcomes and satisfaction.
Koios is a cutting-edge technology company that harnesses the power of artificial intelligence algorithms to revolutionize disease detection and treatment. With over a decade of experience, the company's journey began in 2007 when its skilled engineers successfully adapted radar technology and machine learning to aid the U.S. Army in capturing targets.
Building on this success, Koios directed its expertise towards the early detection of cancer cells, particularly in breast lesions. Its flagship product, Koios DS Breast, stands out as the only FDA-cleared cancer diagnosis software employing AI on breast ultrasound images. Through a vast dataset comprising more than 500,000 ultrasound images of breast lesions linked to pathology results or one-year follow-ups, its proprietary algorithms have been expertly trained. Koios DS Breast serves as a crucial partner to physicians, providing an on-demand second opinion that aids in classifying suspicious lesions and aligning them with the BI-RADS category. The software excels in automatically generating diagnostic reports, streamlining the workflow of interpreting physicians and technicians. Accessible directly on ultrasound scanners or through simple installation and connection to any PACS system, Koios DS delivers insightful feedback that enhances diagnostic accuracy and clinical decision-making. By empowering physicians with the best possible tools, the company aims to improve healthcare outcomes while reducing costs. Koios envisions a future where AI technology paves the way for earlier and more accurate diagnoses, ultimately benefiting both medical practitioners and patients.
Hologic, Inc. is a leading global medical technology company that specializes in providing innovative diagnostic and surgical solutions to improve and enhance women's health. With a rich history dating back to 1985, Hologic has been at the forefront of developing cutting-edge products and services that address a wide range of health issues affecting women, including breast and cervical cancer, osteoporosis, and gynecological conditions. Its diverse portfolio encompasses advanced imaging and diagnostic systems, molecular diagnostic assays, surgical and interventional systems, and women's health screening products. The company holds more than 4,100 patents, indicating a strong focus on developing novel technologies and solutions in the field of medical diagnostics and women's health. The company with a presence in over 100 countries and territories worldwide.
IBM Watson Health has transformed into a new entity called Merative, specializing in healthcare analytics and data solutions. IBM Watson Health and the Watson Health Cloud platform were introduced in April 2015. By showing insights from the enormous amount of personal health data collected and shared every day, the company is assisting doctors, researchers, and insurers in their ability to innovate. IBM Watson Health is a key player in the Global Artificial Intelligence in Breast Imaging Market, providing modern solutions that use AI to improve breast imaging technology.
Besides, the business overview of the organization displays a major emphasis on increasing medical imaging capabilities through the integration of the most advanced artificial intelligence algorithms. IBM Watson Health has been at the forefront of developing AI-powered solutions to help in the early identification and accurate diagnosis of breast cancer.
Additionally, the company's AI-powered breast imaging systems analyze and interpret mammograms, ultrasounds, and other imaging data with high precision and efficiency. The company aims to improve the accuracy of breast cancer screenings, eliminate false positives, and improve radiologists' diagnostic capabilities by introducing AI into the breast imaging workflow.
Furthermore, through strategic ties and collaborations with major healthcare organizations, IBM Watson Health has collected a wealth of data that feeds the development of its AI algorithms. The company's focus on R&D has allowed for continuous advancement of its AI solutions, ensuring that they remain at the forefront of breast imaging technology. The commitment of organizations to intellectual property protection strengthens their position as a significant participant in the AI breast imaging sector. The company's numerous patents indicate its commitment to protecting its exclusive innovations, encouraging trust among consumers and investors.
Riverain Technologies is a pioneer in the research and development of artificial intelligence (AI) technologies for chest imaging. It has developed the first FDA- Cleared Clear Visual Intelligence (CVI) System which enhanced both Detection and reading time for Breast abnormalities.
Riverain Technologies was founded in 2004 as Riverain Medical by Clay Mathile and Richard Glennon, two Dayton-area entrepreneurs and longtime leaders.
Furthermore, Riverain Technology specializes in Image Enhancement Software for Chest X-rays, Image Enhancement Software for Chest CT, Enterprise Solutions, Medical Image Analysis, Machine Learning and Artificial Intelligence.
Additionally, Riverain Technology serves its customers by promising a well-planned and efficiently executed installation by the team. Rapid installation and site-specific setup are made possible by acquisition of normalization technology, programmable routing, and exam filtering tools.
Qure.ai's advanced AI algorithms are designed to analyze and analyze mammograms, ultrasound images, and other breast imaging data with high accuracy and speed. Using the capabilities of deep learning and computer vision, Qure.ai's products assist radiologists in the early detection of breast issues, enabling speedy and exact diagnosis.
Qure.ai presently has one of the most holistic imaging AI portfolios in the world, covering diseases like lung and breast cancer, among others. Currently, the portfolio covers the detection of anomalies in Chest X-rays, Chest CTs, Head CTs, Musculoskeletal X-rays, and Breast Mammograms.
The iCAD Inc. is a medical technology company that specializes in the development and commercialization of advanced cancer detection and treatment solutions. With a focus on improving patient outcomes and enhancing the efficiency of cancer care, the company utilizes innovative technologies, including artificial intelligence and advanced image analysis, to provide cutting-edge medical solutions to healthcare professionals and patients worldwide.
The company's core business centers around cancer detection, particularly in the fields of breast and cervical health. It offers a range of proprietary products and solutions that aid in early cancer detection, providing physicians with crucial information to facilitate timely diagnosis and treatment planning.
Additionally, iCAD's flagship product, the ProFound AI™ platform, stands out as a game-changer in breast cancer detection. Powered by artificial intelligence and deep learning algorithms, ProFound AI™ assists radiologists in accurately interpreting breast tomosynthesis images, commonly known as 3D mammograms. This innovative platform enhances radiologists' ability to identify potential malignancies, leading to improved diagnostic accuracy and reduced false-positive rates. By integrating AI technology into the diagnostic process, iCAD empowers healthcare professionals to make well-informed decisions, ultimately contributing to better patient outcomes.
NVIDIA Corporation is a renowned American technology company that stands at the forefront of the computing and artificial intelligence (AI) industries. Established in 1993 and headquartered in Santa Clara, California, NVIDIA has consistently demonstrated its prowess in designing and manufacturing advanced graphics processing units (GPUs), transforming the landscape of gaming, AI, data centers, and high-performance computing.
With an unwavering commitment to innovation, NVIDIA has become a global leader in GPU technology, offering a diverse range of cutting-edge products and solutions that empower professionals, researchers, gamers, and businesses alike. Leveraging its deep expertise in parallel computing and AI, the company has played an instrumental role in shaping the modern technological landscape, enabling breakthroughs in fields as diverse as healthcare, autonomous vehicles, robotics, and more.
Beyond its impressive hardware offerings, NVIDIA has cultivated a vibrant ecosystem of developers, researchers, and partners, fostering collaboration and creativity in the pursuit of groundbreaking solutions. As an emblem of technological excellence and a driving force behind the AI revolution, NVIDIA continues to push the boundaries of what is possible in the ever-evolving world of computing.
ScreenPoint Medical is a pioneering medical technology company that specializes in the development of deep learning artificial intelligence (AI) solutions for mammography and breast imaging. Founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady, two world-leading experts in quantitative breast image analysis and computer-aided detection, the company has over 40 years of combined experience in the field. Its mission is to leverage cutting-edge AI technology and clinical evidence to enhance breast cancer detection and improve patient outcomes.
The company is a leading medical technology company committed to revolutionizing disease detection and enhancing cancer survival rates on a global scale. Leveraging the power of artificial intelligence (AI) and deep learning, the company specializes in developing cutting-edge solutions for medical image analysis, with a primary focus on breast cancer screening and diagnosis. The company’s leading product is a powerful image analysis platform, designed as a precision adjunct tool for mammography. By integrating advanced AI algorithms, the platform empowers radiologists to accurately detect, quantify, and classify anomalies found in both screening and diagnostic mammograms. Additionally, the company provides advanced imaging solutions for other medical modalities, including MRI, CT scans, and X-rays. Their expertise in AI-driven analysis facilitates the identification of abnormalities that might be overlooked by human interpretation alone, empowering healthcare professionals to make more informed decisions regarding patient care.
